Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals.

Øhrstrøm CC, Hansen DL, Kielgast UL, Hartmann B, Holst JJ, Worm D.

Obes Surg. 2019 Nov 10. doi: 10.1007/s11695-019-04248-x. [Epub ahead of print]

PMID:
31709494
2.

Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide.

Øhrstrøm CC, Worm D, Højager A, Andersen D, Holst JJ, Kielgast UL, Hansen DL.

Diabetes Obes Metab. 2019 Sep;21(9):2142-2151. doi: 10.1111/dom.13796. Epub 2019 Jun 24.

PMID:
31144430
3.

A Response to "The Relationship Between Sleep and Quality of Life in Type 1 Diabetes Patients".

Nørgaard K, Kielgast U.

Diabetes Ther. 2019 Jun;10(3):1173-1174. doi: 10.1007/s13300-019-0622-6. Epub 2019 Apr 26. No abstract available.

4.

Quality of Life is Markedly Impaired by Rheumatological and Skin Manifestations in Patients with Type 1 Diabetes: A Questionnaire Survey.

Nørgaard K, Kielgast U.

Diabetes Ther. 2019 Apr;10(2):635-647. doi: 10.1007/s13300-019-0587-5. Epub 2019 Feb 19.

5.

Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass.

Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Jacobsen SH, Clausen TR, Worm D, Hartmann B, Rehfeld JF, Damgaard M, Madsen JL, Madsbad S, Holst JJ, Hansen DL.

Int J Obes (Lond). 2013 Nov;37(11):1452-9. doi: 10.1038/ijo.2013.15. Epub 2013 Feb 19.

PMID:
23419600
6.

Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass.

Dirksen C, Damgaard M, Bojsen-Møller KN, Jørgensen NB, Kielgast U, Jacobsen SH, Naver LS, Worm D, Holst JJ, Madsbad S, Hansen DL, Madsen JL.

Neurogastroenterol Motil. 2013 Apr;25(4):346-e255. doi: 10.1111/nmo.12087. Epub 2013 Jan 29.

PMID:
23360316
7.

Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects.

Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Worm D, Almdal T, Naver LS, Hvolris LE, Rehfeld JF, Wulff BS, Clausen TR, Hansen DL, Holst JJ, Madsbad S.

Obes Surg. 2012 Jul;22(7):1084-96. doi: 10.1007/s11695-012-0621-4.

PMID:
22359255
8.

Regulation of glucagon secretion by incretins.

Holst JJ, Christensen M, Lund A, de Heer J, Svendsen B, Kielgast U, Knop FK.

Diabetes Obes Metab. 2011 Oct;13 Suppl 1:89-94. doi: 10.1111/j.1463-1326.2011.01452.x. Review.

PMID:
21824261
9.

Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1.

Torekov SS, Ma L, Grarup N, Hartmann B, Hainerová IA, Kielgast U, Kissow H, Rosenkilde M; GIANT Consortium, Lebl J, Witte DR, Jørgensen T, Sandbaek A, Lauritzen T, Madsen OD, Wang J, Linneberg A, Madsbad S, Holst JJ, Hansen T, Pedersen O.

Diabetologia. 2011 Nov;54(11):2820-31. doi: 10.1007/s00125-011-2265-7. Epub 2011 Aug 7.

PMID:
21822931
10.

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.

Kielgast U, Krarup T, Holst JJ, Madsbad S.

Diabetes Care. 2011 Jul;34(7):1463-8. doi: 10.2337/dc11-0096. Epub 2011 May 18.

11.

Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.

Kielgast U, Holst JJ, Madsbad S.

Diabetes. 2011 May;60(5):1599-607. doi: 10.2337/db10-1790. Epub 2011 Mar 25.

12.

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ.

Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5. Review.

PMID:
21208359
13.

Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.

Kielgast U, Asmar M, Madsbad S, Holst JJ.

J Clin Endocrinol Metab. 2010 May;95(5):2492-6. doi: 10.1210/jc.2009-2440. Epub 2010 Mar 5.

PMID:
20207828
14.

Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.

Kielgast U, Holst JJ, Madsbad S.

Curr Diabetes Rev. 2009 Nov;5(4):266-75. Review.

PMID:
19925391
15.

[Peripartum cardiomyopathy in an obese pregnant woman].

Kielgast UL, Schierbeck L, Dümcke C, Al-Amood S, Jensen JE.

Ugeskr Laeger. 2009 Aug 24;171(35):2487-9. Danish.

PMID:
19732539

Supplemental Content

Loading ...
Support Center